Pliant Therapeutics Stock Performance
| PLRX Stock | USD 1.17 0.03 2.63% |
The company holds a Beta of 1.6, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pliant Therapeutics will likely underperform. At this point, Pliant Therapeutics has a negative expected return of -0.65%. Please make sure to check Pliant Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Pliant Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pliant Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Can Pliant Therapeutics Inc. stock double in coming years - July 2025 Institutional Weekly Breakout Watchlists - newser.com | 11/14/2025 |
2 | Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | 12/04/2025 |
3 | Insider Trading | 12/10/2025 |
4 | Can Pliant Therapeutics Inc. stock double in next 5 years - Trade Volume Summary Long-Term Safe Investment Ideas - DonanmHaber | 12/19/2025 |
5 | Pliant Therapeutics CFO sells 225,679 in stock - MSN | 01/12/2026 |
6 | Disposition of 6917 shares by Minnie Kuo of Pliant Therapeutics at 1.28 subject to Rule 16b-3 | 01/20/2026 |
7 | Acquisition by Coulie Bernard of 1230000 shares of Pliant Therapeutics at 1.3 subject to Rule 16b-3 | 01/22/2026 |
8 | Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus | 01/28/2026 |
| Begin Period Cash Flow | 64.7 M | |
| Total Cashflows From Investing Activities | 140.3 M |
Pliant Therapeutics Relative Risk vs. Return Landscape
If you would invest 180.00 in Pliant Therapeutics on November 12, 2025 and sell it today you would lose (63.00) from holding Pliant Therapeutics or give up 35.0% of portfolio value over 90 days. Pliant Therapeutics is currently does not generate positive expected returns and assumes 3.4748% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Pliant, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pliant Therapeutics Target Price Odds to finish over Current Price
The tendency of Pliant Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.17 | 90 days | 1.17 | about 86.81 |
Based on a normal probability distribution, the odds of Pliant Therapeutics to move above the current price in 90 days from now is about 86.81 (This Pliant Therapeutics probability density function shows the probability of Pliant Stock to fall within a particular range of prices over 90 days) .
Pliant Therapeutics Price Density |
| Price |
Predictive Modules for Pliant Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pliant Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pliant Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pliant Therapeutics is not an exception. The market had few large corrections towards the Pliant Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pliant Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pliant Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.57 | |
β | Beta against Dow Jones | 1.60 | |
σ | Overall volatility | 0.17 | |
Ir | Information ratio | -0.14 |
Pliant Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pliant Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pliant Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pliant Therapeutics generated a negative expected return over the last 90 days | |
| Pliant Therapeutics may become a speculative penny stock | |
| Pliant Therapeutics has high historical volatility and very poor performance | |
| Pliant Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (210.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pliant Therapeutics currently holds about 163.6 M in cash with (155.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pliant Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus |
Pliant Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pliant Stock often depends not only on the future outlook of the current and potential Pliant Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pliant Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60.5 M | |
| Cash And Short Term Investments | 355.7 M |
Pliant Therapeutics Fundamentals Growth
Pliant Stock prices reflect investors' perceptions of the future prospects and financial health of Pliant Therapeutics, and Pliant Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pliant Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (111.89 M) | ||||
| Shares Outstanding | 61.45 M | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 3,072 X | ||||
| EBITDA | (205.16 M) | ||||
| Net Income | (210.3 M) | ||||
| Cash And Equivalents | 163.6 M | ||||
| Cash Per Share | 3.36 X | ||||
| Total Debt | 60.19 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.69 X | ||||
| Book Value Per Share | 3.26 X | ||||
| Cash Flow From Operations | (155.5 M) | ||||
| Earnings Per Share | (2.86) X | ||||
| Market Capitalization | 70.05 M | ||||
| Total Asset | 396.95 M | ||||
| Retained Earnings | (710.05 M) | ||||
| Working Capital | 329.05 M | ||||
About Pliant Therapeutics Performance
Evaluating Pliant Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pliant Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pliant Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.57) | (0.59) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (0.80) | (0.76) |
Things to note about Pliant Therapeutics performance evaluation
Checking the ongoing alerts about Pliant Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pliant Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pliant Therapeutics generated a negative expected return over the last 90 days | |
| Pliant Therapeutics may become a speculative penny stock | |
| Pliant Therapeutics has high historical volatility and very poor performance | |
| Pliant Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (210.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pliant Therapeutics currently holds about 163.6 M in cash with (155.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pliant Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus |
- Analyzing Pliant Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pliant Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pliant Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pliant Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pliant Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pliant Therapeutics' stock. These opinions can provide insight into Pliant Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.